|Dr. Michael E. Castagna||CEO & Director||378.41k||N/A||1977|
|Dr. David B. Thomson||Gen. Counsel & Corp. Sec.||458.68k||424.8k||1967|
|Mr. Steven B. Binder||Chief Financial Officer||N/A||N/A||1963|
|Mr. Joseph Kocinsky||Chief Technology Officer||N/A||N/A||1964|
|Ms. Rosabel Realica Alinaya||Sr. VP of Investor Relations & Treasury||N/A||N/A||1961|
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company was founded in 1991 and is headquartered in Westlake Village, California.
MannKind Corporation’s ISS Governance QualityScore as of April 1, 2018 is 6. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 3; Compensation: 5.